Total Payments
$296,444
2024 Payments
$4,085
Companies
60
Transactions
893
Medicare Patients
3,872
Medicare Billing
$307,695
Payment Breakdown by Category
Research$254,592 (85.9%)
Food & Beverage$29,477 (9.9%)
Travel$11,765 (4.0%)
Consulting$512.00 (0.2%)
Education$97.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $254,592 | 65 | 85.9% |
| Food and Beverage | $29,477 | 773 | 9.9% |
| Travel and Lodging | $11,765 | 46 | 4.0% |
| Consulting Fee | $512.00 | 1 | 0.2% |
| Education | $97.59 | 8 | 0.0% |
Payments by Type
Research
$254,592
65 transactions
General
$41,852
828 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $201,680 | 27 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $39,518 | 4 | $0 (2020) |
| Eli Lilly and Company | $12,396 | 20 | $0 (2023) |
| Novo Nordisk Inc | $5,664 | 144 | $0 (2024) |
| Abbott Laboratories | $3,738 | 35 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $3,704 | 51 | $0 (2024) |
| Novo Nordisk AS | $3,662 | 21 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $2,941 | 93 | $0 (2024) |
| ABBVIE INC. | $2,598 | 41 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $2,033 | 35 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,085 | 57 | ABBVIE INC. ($1,822) |
| 2023 | $5,986 | 75 | Novo Nordisk AS ($1,800) |
| 2022 | $12,875 | 95 | Eli Lilly and Company ($9,170) |
| 2021 | $74,179 | 78 | SANOFI US SERVICES INC. ($69,170) |
| 2020 | $25,022 | 59 | SANOFI US SERVICES INC. ($11,877) |
| 2019 | $67,424 | 149 | SANOFI US SERVICES INC. ($52,494) |
| 2018 | $90,050 | 175 | SANOFI US SERVICES INC. ($68,139) |
| 2017 | $16,823 | 205 | Regeneron Pharmaceuticals, Inc. ($7,175) |
All Payment Transactions
893 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: VACCINES | ||||||
| 11/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Diabetes | ||||||
| 09/26/2024 | PFIZER INC. | VYNDAMAX (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $581.31 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $235.69 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $123.40 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $111.15 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $14.07 | General |
| 09/21/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $172.53 | General |
| 09/16/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: VACCINES | ||||||
| 09/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $6.65 | General |
| Category: Cardio-renal | ||||||
| 09/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.88 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2024 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: VACCINE | ||||||
| 07/25/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $88.98 | General |
| 06/25/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Diabetes | ||||||
| 06/18/2024 | Boston Scientific Corporation | myLUX Patient Kit with mobile device (Device) | Food and Beverage | In-kind items and services | $101.80 | General |
| Category: myLUX_CRM | ||||||
| 06/18/2024 | Boston Scientific Corporation | BodyGuardian (Device) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: CDS - Holter Monitoring_RM | ||||||
| 06/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: Cardio-renal | ||||||
| 06/11/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Diabetes | ||||||
| 05/28/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $13.06 | General |
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Respiratory | ||||||
| 05/13/2024 | Boston Scientific Corporation | BodyGuardian (Device) | Food and Beverage | In-kind items and services | $41.14 | General |
| Category: CDS - Holter Monitoring_RM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | SANOFI US SERVICES INC. | $98,198 | 10 |
| Eff-CVOT | SANOFI US SERVICES INC. | $67,181 | 5 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $36,301 | 12 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $18,785 | 2 |
| Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial | Regeneron Pharmaceuticals, Inc. | $12,634 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | Regeneron Pharmaceuticals, Inc. | $8,098 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $7,677 | 2 |
| NN SELECT Results Meeting Philadelphia | Novo Nordisk AS | $1,800 | 11 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,794 | 15 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $1,316 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $297.54 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $225.11 | 1 |
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $173.25 | 1 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | Eli Lilly and Company | $111.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,028 | 1,207 | $197,921 | $89,753 |
| 2022 | 11 | 1,023 | 1,233 | $196,231 | $84,748 |
| 2021 | 10 | 1,069 | 1,259 | $193,523 | $82,246 |
| 2020 | 11 | 752 | 882 | $153,521 | $50,947 |
Total Patients
3,872
Total Services
4,581
Medicare Billing
$307,695
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 163 | 292 | $65,408 | $29,008 | 44.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 139 | 139 | $48,094 | $20,127 | 41.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 99 | 139 | $24,881 | $10,112 | 40.6% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 41 | 41 | $14,025 | $9,609 | 68.5% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 82 | 84 | $12,020 | $7,190 | 59.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 60 | 60 | $4,800 | $4,543 | 94.6% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 144 | 144 | $6,912 | $3,059 | 44.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 119 | 119 | $4,165 | $2,528 | 60.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 60 | 60 | $2,100 | $2,058 | 98.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 110 | 117 | $14,976 | $1,378 | 9.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 12 | $540.00 | $141.24 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 344 | $77,056 | $32,153 | 41.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 153 | 153 | $52,938 | $22,937 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 103 | $18,437 | $6,648 | 36.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 71 | 73 | $5,700 | $5,004 | 87.8% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 18 | 18 | $5,875 | $4,590 | 78.1% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 153 | 153 | $5,355 | $3,302 | 61.7% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 40 | 40 | $5,700 | $3,243 | 56.9% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 133 | 133 | $6,396 | $2,944 | 46.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 72 | 74 | $2,590 | $2,540 | 98.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 117 | 118 | $15,104 | $1,093 | 7.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 24 | $1,080 | $295.45 | 27.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 173 | 315 | $70,560 | $31,956 | 45.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 162 | 162 | $56,052 | $24,820 | 44.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 96 | 135 | $24,165 | $9,180 | 38.0% |
About Dr. Stephen Ong, MD
Dr. Stephen Ong, MD is a Surgery healthcare provider based in Oxon Hill, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851479281.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Ong, MD has received a total of $296,444 in payments from pharmaceutical and medical device companies, with $4,085 received in 2024. These payments were reported across 893 transactions from 60 companies. The most common payment nature is "" ($254,592).
As a Medicare-enrolled provider, Ong has provided services to 3,872 Medicare beneficiaries, totaling 4,581 services with total Medicare billing of $307,695. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgery
- Other Specialties Family Medicine
- Location Oxon Hill, MD
- Active Since 11/02/2006
- Last Updated 05/10/2011
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1851479281
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $67,181
- SAR439977 (Drug) $53,452
- PRALUENT (Biological) $19,709
- PRALUENT ALIROCUMAB INJECTION (Biological) $12,759
- Ozempic (Drug) $4,700
- FARXIGA (Drug) $2,325
- KRYSTEXXA (Biological) $1,825
- Pacemakers (Device) $1,820
- ARMOUR THYROID (Drug) $1,581
- ELIQUIS (Drug) $1,451
- JARDIANCE (Drug) $1,344
- LEQVIO (Drug) $1,292
- Xultophy 100/3.6 (Drug) $996.40
- Tresiba (Drug) $962.37
- JANUVIA (Drug) $726.42
- XARELTO (Drug) $720.31
- ENTRESTO (Drug) $601.59
- TOUJEO (Drug) $543.80
- TRULICITY (Drug) $483.40
- Vascepa (Drug) $461.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.